Rani Therapeutics and ProGen partner on GLP-1/GLP-2 dual agonist PG-102 in RaniPill HC for weight management

Rani Therapeutics Holdings, Inc.

Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.
ProGen supplies PG-102; Rani manufactures final Product (Device + compound) worldwide.
Each party can opt-out anytime; continuing party pays low single to mid-single digit royalties on net sales post opt-out.
Priority regulatory markets include US, EU, UK, Canada, Australia, Japan, and South Korea.
Rani leads preclinical through Phase 1 globally; commercial rights split by assigned territories.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.